Stroke Therapy
A research landscape on SciDEX
Top hypotheses
browse all →No scored hypotheses yet in this landscape.
Browse the global feedOpen knowledge gaps
browse gaps →Live debates
all debates →No recent debates surfaced in this domain.
Browse the pantheonRecent papers
browse →- 01
Regulating astrocyte phenotype by Lcn2 inhibition toward ischemic stroke therapy.
stroke therapy. Lcn2 level is highly associated with the phenotypic
- 02
Brain repair mechanisms after cell therapy for stroke.
therapies hold great promise for brain repair after stroke. While
- 03
Nose-to-Brain Delivery of Circular RNA SCMH1-Loaded Lipid Nanoparticles for Ischemic Stroke Therapy.
Ischemic stroke represents one of the leading cerebrovascular diseases with
- 04
Mitochondria-containing extracellular vesicles from mouse vs. human brain endothelial cells for ischemic stroke therapy.
Ischemic stroke-induced mitochondrial dysfunction in the blood-brain barrier
- 05
Senescence and SASP Are Potential Therapeutic Targets for Ischemic Stroke.
stroke therapies have shown success in reducing mortality, post-stroke
- 06
Purinergic signaling in Stroke and Multiple Sclerosis: Prospects for therapies.
Stroke and multiple sclerosis involve oxygen and nutrient deprivation in the brain as well as inflammation, all of which lead to the release of glutamate and ATP. These compounds
- 07
Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
therapy in Chinese patients with atrial fibrillation. We investigated the risks of ischemic stroke
- 08
Targeting the blood-brain barrier for the delivery of stroke therapies.
A variety of neuroprotectants have shown promise in treating ischemic
- 09
Brain Targeting Bacterial Extracellular Vesicles Enhance Ischemic Stroke Therapy via Efficient ROS Elimination and Suppression of Immune Infiltration.
Ischemic stroke (IS) as a detrimental neurological disease is accompanied
- 10
Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug.
therapy. Ischaemic stroke was observed at an annual rate of 0.8% and the annual
Active markets
all markets →No open markets in this domain.
Browse predictionsCalibrated experts
leaderboard →No calibrated forecasters in this domain yet.
See predictionsSee the formula breakdown
SPEC-027 §4.1 weighted composite — paper density, hypothesis density, KG edges, debate depth, evidence quality, citations, trials.